Therapeutic anticoagulation is indicated for a variety of circumstances and conditions in
several fields of medicine to prevent or treat venous and arterial thromboembolism …

Despite advances in anticoagulant therapy, thrombosis remains the leading cause of
morbidity and mortality worldwide. Heparin and vitamin K antagonists (VKAs), the first …

Background Phase II randomized controlled trials (RCTs) on factor (F) XI inhibitors have
shown promising results but they were burdened by low statistical power for clinical …

Hemostasis and thrombosis are believed to be so intricately linked that any strategies that
reduce thrombosis will have an inevitable impact on hemostasis. Consequently, bleeding is …

Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not
completely effective, and concerns about the risk of bleeding continue to limit their uptake …

Although anticoagulation therapy has evolved from non-specific drugs (ie, heparins and
vitamin K antagonists) to agents that directly target specific coagulation factors (ie, direct oral …

Although anticoagulation without hemorrhage is a primary aim, this vision has remained as
yet out of reach. Even despite the superior safety profile of the direct oral anticoagulants …

FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have
the potential to be both more efficacious and safer than the currently available direct oral …

Abstract Factor XI/XIa (FXI/FXIa) represents a potential target for improved precision in
anticoagulation because it is involved primarily in thrombus formation and plays a much …

During the past decade, emergence of direct oral anticoagulants (DOACs) has drastically
improved the prevention of thrombosis. However, several unmet needs prevail in the field of …